Oncotarget

Research Papers:

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid

Birthe Heitkötter _, Konrad Steinestel, Marcel Trautmann, Inga Grünewald, Peter Barth, Heidrun Gevensleben, Martin Bögemann, Eva Wardelmann, Wolfgang Hartmann, Kambiz Rahbar and Sebastian Huss

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:9867-9874. https://doi.org/10.18632/oncotarget.23984

Metrics: PDF 878 views  |   HTML 1917 views  |   ?  


Abstract

Birthe Heitkötter1,*, Konrad Steinestel2,*, Marcel Trautmann1, Inga Grünewald1, Peter Barth1, Heidrun Gevensleben3, Martin Bögemann4, Eva Wardelmann1, Wolfgang Hartmann1, Kambiz Rahbar5 and Sebastian Huss1

1Gerhard Domagk Institute of Pathology, University of Münster, Münster, Germany

2Institute of Pathology, Military Hospital Ulm, Ulm, Germany

3Institute of Pathology, Neuss, Germany

4Department of Urology, University Hospital Münster, University of Münster, Münster, Germany

5Department of Nuclear Medicine, University Hospital Münster, Münster, Germany

*These authors contributed equally to this work

Correspondence to:

Sebastian Huss, email: sebastian.huss@ukmuenster.de

Keywords: PSMA; thyroid cancer; tumor neoangiogenesis; prostate cancer

Received: July 26, 2017     Accepted: November 15, 2017     Published: January 04, 2018

ABSTRACT

Aim: PSMA (prostate-specific membrane antigen) is physiologically expressed in normal prostate tissue and over expressed in prostate cancer cells, therefore constituting a potential target for antibody-based radioligand therapy. Very recent imaging findings reported PSMA-PET/CT uptake in various thyroid lesions. We were therefore encouraged to systematically analyse PSMA expression in different benign and malignant thyroid lesions.

Methods: Immunohistochemistry was used to detect PSMA expression in 101 thyroid lesions, while neovasculature was identified by CD34 immunostaining.

Results: PSMA expression in the neovasculature was significantly more frequent in malignant tumors (36/63; 57.1%) compared to benign diseases (5/38; 13.2%; p = 0.0001). In addition, PSMA expression levels in the neovasculature of poorly and undifferentiated thyroid cancers were significantly higher compared to differentiated thyroid tumors (p = 0.021). However, one case with a strong expression in follicular adenoma was identified.

Conclusions: We conclude that neovascular PSMA expression is common in thyroid cancer but may also rarely be found in benign thyroid diseases, such as follicular adenoma. High expression in the tumor-associated neovasculature is predominantly found in poorly differentiated and undifferentiated (anaplastic) thyroid cancer. This knowledge is highly relevant when interpreting PSMA/PET-CT scans from patients with prostate cancer. In addition, our findings might provide a rationale for further evaluation of PSMA-targeted anti-neovascular or radioligand therapy in metastatic dedifferentiated thyroid cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23984